Title : Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

Pub. Date : 2013 Nov 12

PMID : 24215511






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens
2 BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens
3 BACKGROUND: The purpose of the present study was to retrospectively evaluate whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients. gemcitabine ribonucleotide reductase catalytic subunit M1 Homo sapiens